An Open-label Multicenter Rollover Study to Provide Continued Treatment to Participants Previously Enrolled in a RVU120 Clinical Study
Phase 2 – studying effectiveness and dosage
Conditions:
Relapsed / Refractory Metastatic or Advanced Solid Tumors
Myelofibrosis
Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Acute Myeloid Leukemia with or without NPM1 Mutation
Sponsor: Ryvu Therapeutics S.A.
trial.available_in:
БГ
Overview
Trial status: Authorised
Time from the first administration of RVU120-based treatment in the parent study until discontinuation of RVU120-based treatment for any reason in the rollover study
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Description
Time from the first administration of RVU120-based treatment in the parent study until discontinuation of RVU120-based treatment for any reason in the rollover study
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 29 participants
БГ